Methotrexate topical - MediQuest Therapeutics
Alternative Names: MQX-5902; MQX-5904; MQX-5906Latest Information Update: 21 Jan 2022
At a glance
- Originator MediQuest Therapeutics
- Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 17 Sep 2015 No recent reports on development identified - Phase-II for Psoriasis in United Kingdom (Topical)
- 28 Aug 2012 Methotrexate topical - MediQuest Therapeutics is available for licensing as of 28 Aug 2012. http://www.mqti.com